Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
My WAG is .75-.80 before the weekend.
Guess I should of sold at $14 years ago
It will. Just a matter of time. Can’t stop a penny stock with this share structure when it does start flying. Plenty of us here holding millions and have been..
Great read. Thanks for the link
Looks like you’ll have to pay up as the price won’t fall to .XX.
Should see another nice pop tomorrow and into next week.
Nice work LEO and IPIX
No one cares
Still dumping and price is going up...
Your DD is terrible. Can’t wait til this hits $2 again. Going to burn some shorties
That is huge! That should attract a large number of buyers and we will be rolling to multiple pennies.
Monster in the making. So many catalyst over the next few weeks.
$$RSHN$$
This isn’t a fact based forum. Speculations run wild as you know. However, this theory is just as plausible as the next poster. In fact, it’s much more likely that manipulation has negatively effected the share price compared to the actions of management as many proclaim.
Multiple dollars share price in the near future. $$$ GO IPIX
I rarely say this ss, but that was kind of funny. Even if it was coming from you. Kudos
Where do find that the partner is dumping shares? I’m sure this is your opinion and a wild baseless speculation.
I guess paid subscribers like to hear opinions for a proclaimed “pro”. Lmao!!!
Go Leo.
Innovation Pharmaceuticals Secures Up to $10 Million in Additional Financing to Advance Clinical Pipeline
BEVERLY, MA – October 9, 2018 (GLOBE NEWSWIRE) Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that it has secured new financing for up to $10 million from one multi-family office focused on healthcare and life sciences, including an initial net placement of approximately $2.2 million over the first 30 days. These funds will be used to continue to advance the Company’s pipeline of first-in-class drug candidates: Brilacidin for Oral Mucositis, Kevetrin for Ovarian Cancer and Prurisol for Psoriasis.
The Company entered into a Securities Purchase Agreement pursuant to which the Company agreed to sell preferred stock that is convertible to its Class A common stock and warrants in a registered direct offering (the “Offering”), without an underwriter or placement agent. The first tranche of the Offering is anticipated to close on October 9, 2018. For additional information about the Securities Purchase Agreement, refer to the current report on Form 8-K filed on October 9, 2018 with the Securities and Exchange Commission.
The Offering was registered pursuant to the Company’s effective Shelf Registration Statement on Form S-3 (File No. 333-220419) (the “Registration Statement”) and the related base prospectus included in the Registration Statement, as supplemented by the prospectus supplement dated October 5, 2018.
“This new financing serves to further bolster our balance sheet and gives us flexibility in working to meet our near-term goals, which includes advancing Brilacidin into a pivotal study,” said Leo Ehrlich, Chief Executive Officer of Innovation Pharmaceuticals. “The Company is at an exciting juncture, with our three novel drug candidates successfully reaching mid- and later-stage trials across multiple indications representing large market opportunities. We remain steadfast in delivering innovative medicines to patients and increasing the Company’s valuation.”
This press release is for informational purposes only and is not an offer to sell or purchase nor the solicitation of an offer to sell or purchase securities and shall not constitute an offer, solicitation or sale in any state or jurisdiction in which, or to any person to whom, such an offer, solicitation or sale would be unlawful.
Alerts
Sign-up for Innovation Pharmaceuticals email alerts is available at:
http://www.ipharminc.com/email-alerts/
About Innovation Pharmaceuticals
Innovation Pharmaceuticals Inc. (IPIX) is a clinical stage biopharmaceutical company developing a world-class portfolio of innovative therapies addressing multiple areas of unmet medical need, including inflammatory diseases, cancer, infectious disease, and dermatologic diseases. Brilacidin, a versatile compound with broad therapeutic potential, is in a new chemical class called defensin-mimetics. A Phase 2 trial of Brilacidin as an oral rinse for the prevention of Severe Oral Mucositis (SOM) in patients with Head and Neck Cancer, met its primary and secondary endpoints, including reducing the incidence of SOM. Positive results were also observed in a Phase 2 Proof-of-Concept trial treating patients locally with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis. A Phase 2b trial of Brilacidin showed a single intravenous dose of the drug delivered comparable outcomes to a seven-day dosing regimen of the FDA-approved blockbuster daptomycin in treating Acute Bacterial Skin and Skin Structure Infections. Kevetrin is a novel anti-cancer drug shown to modulate p53, often referred to as the “Guardian Angel Gene” due to its crucial role in controlling cell mutations, and has successfully completed a Phase 2 trial in ovarian cancer. Prurisol, an oral psoriasis drug candidate acting through immune modulation and PRINS reduction, has now completed a Phase 2b trial and is awaiting statistical analysis. More information is available on the Company website at www.IPharmInc.com.
Forward-Looking Statements: This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 including statements concerning projected timelines for the initiation and completion of clinical trials, our future drug development plans, other statements regarding future product developments, including with respect to specific indications, the anticipated total proceeds from the Offering, the exercise of any warrants, and any other statements which are other than statements of historical fact. These statements involve risks, uncertainties and assumptions that could cause the Company’s actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. The Company has in some cases identified forward-looking statements by using words such as “anticipates,” “believes,” “hopes,” “estimates,” “looks,” “expects,” “plans,” “intends,” “goal,” “potential,” “may,” “suggest,” and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are the Company’s need for, and the availability of, substantial capital in the future to fund its operations and research and development; including the amount and timing of the sale of shares of common stock to Aspire Capital; the fact that the Company’s compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in the Company’s filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. The Company undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.
Copyright © 2018 Innovation Pharmaceuticals, All rights reserved.
You requested to receive email alerts about Innovation Pharmaceuticals at our website http://www.ipharminc.com/
Our mailing address is:
Innovation Pharmaceuticals
100 Cummings Center, Suite 151-B
Beverly, MA 01915
Add us to your address book
Email Marketing Powered by Mailchimp
unsubscribe from this list | update subscription preferences
Image
Awesome news!! Well done Leo! The shorts should feel a little burn today.
Should be hearing more news in the coming weeks as positive developments unfold.
Go iPix.
Please send a list of biotech stocks with comparable platforms. Thanks dud, look forward to reading that list.
Solid posts Nerby. Thanks for the good read.
Must be frustrating for the posters creating FUD and the share price goes up. I think the problem is their DD is flawed.
Probably best to buy or move on. It’s not dropping going into MJ season..
What’s the issue?!? I’ve already explained myself and my opinions. Not ideal cash position but this story is far from over. New chapter to be written soon. It’s the usual bears creating FUD and speculative theories. Nuff said
Please provide objective post of why you should keep your position and I’ll provide an objective post on why I should sell? Capisce?
Doc, your patients need you. Get off iHub while working rounds.
All opinion and hearsay. The fact that he’s staying on as a director seems to me that the he did go out gracefully.
We could also speculate that if he resigned that there were issues he didn’t agree with.
You obviously spend a great deal of time researching and theorizing on every decision that this company makes. You should direct your inquiries with the company as a concerned shareholder.
Then your best course of action should be to sell and move on. Seems like the fool would be an investor who doesn’t believe in management or the science but still keeps his/her position. Do understand your posts carry zero weight.. Filled with false information and conjecture at best.
Price is going to soar this week. You should probably inform your subscribers that it’s time to BUY.
GO IPIX$
http://www.ipharminc.com/press-release/2016/12/14/p87o1t8af2wn9fxtnapze33i3z6z29
You may want to reread this PR. FDA awarded Kevetrin Orphan Drug status for Ovarian cancer which means it’s far from dead. Only a matter of time before you’re wishing you bought shares of IPIX. Btw-Your DD is terrible.
Thanks George. The most promising Biotech I’ve seen in a long time. Funding will be secured soon and expecting BTD by the FDA as well. The partnership deal with the global pharmaceutical company will be a game changer for this stock. Exciting times ahead.
Go Leo and IPIX
I see the bears are out in full force today.
Good news is coming $$
It’s going to be painful for some when this deal drops.
Think of REGN, anacor, srpt, and many others. It’s going to be pretty exciting
Buying on Monday would make you look smart
You do realize that a 10k or 10q has the “cya” literature in there right?!? They always provide worst case scenario...
Most of the folks posting aren’t invested in IPIX anyways and the others that are questioning management should sell and move on.
Pony up. Go IPIX$$
This is a management that believes in the drugs and pipeline. Collectively they decided on these business decisions and thought this was the best path forward. If that wasn’t the case, you are right, the executives would have already left..
Up we go from here. $$
Yeah it’s too funny. MM’s playing games. This will run 100% soon$$
Thanks Boodog. I as well. I have been adding.
Not pleased with the price but excited to add at these levels.
Details will follow regarding the pharma deal. I anticipate a few unexpected positive surprises coming from IPIX$$
Deal is in the works
“The Company signed a non-binding term sheet in August 2018 with a global pharmaceutical company for the licensing/rights to Brilacidin for treating oral mucositis and inflammatory bowel diseases. Initial payments, milestone payments and royalties are being negotiated in accordance with the non-binding term sheet. The pharmaceutical company is now engaged in further due diligence. Management can offer no assurances that the parties will enter into a binding definitive agreement. “
Please sticky to the top
Great posts balamidas! RSHN has a long way to run$$
That sounds about right Daubers. Picked up 30k shares today. Adding to the stash. Should be a fun rest of the year. $$$
How is he your leader?!? One usually has to be invested first.
Time to buy$$
See ya SS
Deal is in the works$$$
The Company signed a non-binding term sheet in August 2018 with a global pharmaceutical company for the licensing/rights to Brilacidin for treating oral mucositis and inflammatory bowel diseases. Initial payments, milestone payments and royalties are being negotiated in accordance with the non-binding term sheet. The pharmaceutical company is now engaged in further due diligence. Management can offer no assurances that the parties will enter into a binding definitive agreement.
Should be hearing announcement details soon.
Haha. We will be green tomorrow$$
“We have entered into multiple non-disclosure agreements with pharmaceutical companies that enable us to continue ongoing discussions regarding potential partnering should the trial results support such a relationship.”
Details to follow$$
Deal is in the works$$$
The Company signed a non-binding term sheet in August 2018 with a global pharmaceutical company for the licensing/rights to Brilacidin for treating oral mucositis and inflammatory bowel diseases. Initial payments, milestone payments and royalties are being negotiated in accordance with the non-binding term sheet. The pharmaceutical company is now engaged in further due diligence. Management can offer no assurances that the parties will enter into a binding definitive agreement.
Should be hearing announcement of deal very soon
Go IPIX
Company is finalizing deals as we speak. Details to follow soon.